Huayu Cancer Detection and Treatment Eyes on the Asian market
Lin Liangguang, general manager of Uni Pharma, emphasizes asset-light and stable operating performance. Photo/Zhang Bingfeng
Uni Pharma (6621), which has been established for 17 years, focuses on tumors, focusing on detection, ablation therapy, clinical chemotherapy drug monitoring, neurological testing, new drug development, medical supplies and other fields, and is committed to building a complete product line. In recent years, a number of new diagnostic reagents, medical devices and drugs have successively obtained TFDA and foreign marketing authorizations, driving the steady growth of operations year by year, and in 2017, Huayu will be based on the local market and focus on the Asian market.
Uni Pharma currently has a share capital of 263 million yuan, with Chen Zheng, chairman of the board, Lin Liangguang, general manager, Jianya, the main corporate shareholder, holding 12.46% of the shares, Guanding Investment holding 5.45%, Yuanta Asia Investment holding 3.81%, and Zhaofeng Silver holding 3.81%, with a total of 36 employees, which is a small and medium-sized medical drug R&D and sales industry.
In recent years, Huayu has been acting as an agent for the sale of international drugs from the beginning, further introducing cancer detection reagents, treatment equipment, and medical materials, and actively investing in the research and development of new cancer drugs and reagents. Huayu’s products are mainly self-financed projects, supplemented by health insurance payment projects. Recently, Huayu has set up a medical testing laboratory, which will provide molecular testing and pharmaceutical product quality assurance verification services.
In 2015, Huayu’s operation grew significantly, with a revenue of 136 million yuan, an annual increase of more than 5 percent, and officially turned losses into profits; medical equipment, drugs, and diagnostic reagents accounted for 71%, 21%, and 8% respectively, and the legal person estimated that Huayu’s operation is expected to rise steadily in 2016, and in 2017, new products such as tumor ablation systems, drugs, and diagnostic reagents will be supported by business opportunities, and revenue growth will continue to be optimistic.
In early December, Huayu’s shares were publicly issued, and it plans to enter the OTC market in the first quarter of next year and enter Taiwan’s OTC capital market within two years.
At present, the main products listed by Huayu are: Kanglijie 4-MP new drug, Adept postoperative mucosity solution, RFA tumor ablation system, DR-70 colorectal cancer postoperative monitoring marker, EZ Detect home simple fecal occult blood test strip, Cervi-M cervical cancer methylation gene detection, Bain inj. morphine analgesics, etc. This year, the certification of new medical materials and drugs and the expansion of domestic and foreign markets have made great gains, accumulating momentum for operational growth in 2017.
For example, the RFA tumor ablation system, which has been included in Taiwan’s health insurance benefits and is widely adopted by hospitals and physicians, is a key product for Huayu’s revenue growth next year. In addition to being marketed in Taiwan, DR-70 tumor markers have been approved for marketing in Turkey, India, Indonesia, Thailand and other countries in the past one year, and will be supplied to 30 countries in Asia with its own brand of cancer diagnostic reagents.
The only home-based fecal occult blood test strip was launched in Taiwan in the third quarter, and the Asian market demand is expected to be a big business opportunity. In April, Kanglijie 4-MP antidote new drug obtained TFDA license, which is the first step in the research and development of Huayu’s new drug. In the future, we will continue to develop new oral drugs for the treatment of alcoholic hepatitis and the prevention of liver cancer and esophageal cancer.
(Business Times)
